The Latest Breaking News from Novo Nordisk

Novo Nordisk's long-term strategy for weight-loss treatments has earned praise from scientists, even as investors grow cautious about timelines, competition and near-term returns.

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

Asian shares are mixed in thin holiday trading, with most markets in the region and elsewhere closed for Christmas

The Wegovy pill has been approved, but questions over cost and access could shape who benefits from the new oral weight-loss treatment.

Availability of oral pills to treat obesity could expand the booming market for obesity treatments by broadening access and reducing costs, experts said.

U.S. regulators have approved a pill version of the weight-loss drug Wegovy, a boon for drugmaker Novo Nordisk

Oral Wegovy could provide a more convenient and cheaper alternative to the injectable version.

Companies say the EU’s deregulation efforts are insufficient against Trump's “carrot-and-stick” strategy of pairing generous US tax incentives with a punitive 15% tariff on imports from the EU.

New pricing deals and aggressive marketing are transforming GLP-1s.

Semaglutide, the drug behind the blockbuster weight-loss jabs Ozempic and Wegovy, does not slow cognitive decline in people with early-stage Alzheimer’s, according to two large new studies. The results close the door, for now, on hopes that a treatment for diabetes and obesity might also help protect the brain.

On Wednesday, Novo Nordisk A/S (NYSE:NVO) submitted its supplemental marketing application to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg for chronic weight management.